Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...

Ipsen’s Iqirvo (elafibranor) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat ...

AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in ...

Medscape Education showcases its strong track record in providing high-quality education in the field of pulmonology at the ...

Why Patient Perspectives Matter: Driving Success in Clinical Trials”! We’re thrilled to have Wendy Erler and Alfred Samuels ...

Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s ...

One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study ...

Diversity and inclusion are critical to business success, particularly when fostering innovation and creativity. At Mednet, ...

Keytruda works by increasing the ability of the body’s immune system to help detect and fight tumour cells, and is already approved as a monotherapy and in combination regimens for certain patients ...

GSK’s Arexvy has been shown to protect older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) over three full RSV seasons. Results from the phase 3 ...

Johnson & Johnson’s (J&J) Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission (EC) as a long-term treatment for pulmonary ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...